Access detailed search options for content from the Clinical Journal of Oncology Nursing & Oncology Nursing Forum below.
IV infusion remains a primary means of administering antineoplastic therapy. The presence of an IV access device and the administration of certain types of medication can result in complications. This course reviews risk factors, manifestations of complications, and prevention strategies for vascular access devices.
ONS member Cyndy Simonson, MS, APRN-BC, AOCN®, oncology nurse practitioner who is the nursing editor at Duke Regional Hospital in Durham, NC, and member of the North Carolina Triangle ONS Chapter, joins Stephanie Jardine, BSN, RN, oncology clinical specialist at ONS, to discuss biomarker testing for patients with cancer and how it affects targeted therapy regimens during treatment. The advertising messages in this episode are paid for by G1 Therapeutics, Inc.
The drug reference sheets in ONS Voice are a quick guide to newly approved therapies or drugs with new indications. This resource from ONS clinical staff provides information through a nursing lens and includes the drug’s indication, side-effect profile, nursing considerations, patient education talking points, and more.
Oral anticancer medications (OAMs) have been used for decades to treat and reduce the risk of a variety of cancers. With the exponential increase in the number of oral medications developed, including cytotoxic agents, hormonal agents, small-molecule inhibitors, and agents targeted at receptors that regulate cellular differentiation and growth, cancer programs are developing workflows, education, and symptom management programs to ensure that patients follow their prescribed treatments. As a result, clinicians need evidence-based guidelines to assist patients in achieving the best possible outcomes as nonadherence to OAMs can lead to suboptimal responses to therapy.
As the use of CAR T-Cell therapy grows, understanding the events involved, the adverse events associated with this therapy and evidence-based management strategies is critical. Use this resource to enhance your understanding of the process behind CAR T-Cell therapy and nursing considerations associated with the treatment.
During two March 2023 focus group discussions, 14 oncology nurses shared their experiences with caring for patients receiving CAR T-cell therapy in hematologic malignancies. The discussions were conducted to help ONS identify and assess the key nursing issues, trends, and barriers related to the use of CAR T-cell therapy in hematologic malignancies and identify strategies to support oncology nurses in clinical practice.
In August 2021, ONS brought together 17 oncology nurses to discuss their experiences with immuno-oncology, precision oncology, and nurse navigation. The goal was to assess their understanding of and identify gaps related to precision oncology and the role of the nurse navigator. This clinical update summarizes the findings of the focus group proceedings.
ONS member Pam Grubbs, APRN, CNS, MS, AOCNS®, clinical nurse specialist and assistant professor in nursing at Mayo Clinic College of Medicine and Science in Rochester, MN, and member of the ONS Southeast Minnesota Chapter, and Stephanie Jardine, BSN, RN, oncology clinical specialist at ONS, discuss radioactive targeted therapies, safety recommendations, and common misconceptions.